Leads Biolabs Doses First Patient in Opamtistomig Colorectal Cancer Trial
Leads Biolabs said the first patient has been dosed in an open-label Phase Ib/II combination trial of its PD-L1/4-1BB bispecific antibody in metastatic colorectal cancer.
Leads Biolabs said the first patient has been dosed in an open-label Phase Ib/II combination trial of its PD-L1/4-1BB bispecific antibody in metastatic colorectal cancer.